Heparin inhibits smooth muscle cell (SMC) proliferation after arterial injury by mechanisms that have yet to be defined. Since the initiation of SMC proliferation is mediated by basic fibroblast growth factor (bFGF), we have investigated the possibility that heparin inhibits SMC proliferation by displacing bFGF from the arterial wall. Using a rat carotid artery model of balloon catheter injury, we demonstrate that a bolus injection of heparin depletes the arterial wall of both systemically administered bFGF and of endogenous bFGF. Heparin, however, does not reduce the bFGF content of unmanipulated arteries. Further, a single injection of heparin given at the time of balloon injury reduces SMC proliferation by 55% but has no effect when given 6 h after injury. SMC proliferation induced in a denuded artery by injection of bFGF is inhibited almost completely by a bolus injection of heparin; however, pretreatment with a bolus of heparin does not prevent SMC from responding to a subsequent bolus of bFGF. These experiments suggest that heparin can inhibit SMC proliferation in part by removal of released bFGF from sites of injury. (J. Clin. Invest. 1992. 
Introduction
A common problem after angioplasty is the occurrence ofrestenosis ( 1, 2) , which is mediated in part by proliferation ofvascular smooth muscle cells (SMC)'. Much attention has focused on understanding the processes involved in the proliferation of arterial SMCs (3) (4) (5) and we have recently found that SMC replication is significantly inhibited (> 80%) by an antibody to basic fibroblast growth factor (bFGF) (6) in an injury model of the rat carotid artery. This observation demonstrates that bFGF released from damaged cells is responsible for the initiation of medial SMC proliferation.
Heparin has been shown to be an effective inhibitor ofSMC proliferation and intimal thickening in the ballooned rat carotid artery (7-1 1 ). How heparin inhibits SMC proliferation is still unclear. It is known that heparin binds to bFGF, forming a bFGF-heparin complex and protecting the growth factor from degradation ( 12). In culture, bFGF can be displaced from extracellular matrix binding sites by heparin ( 13, 14) , and in vivo, bFGF displaced by this mechanism could then be cleared through metabolic pathways in the liver and kidney (15) . Thus, in vivo heparin might displace bFGF from its matrix binding sites and clear it from the artery wall. The aim ofthese experiments was to study the interaction ofheparin with bFGF and investigate the mechanism of how heparin inhibits SMC proliferation after balloon injury in vivo.
Methods
Male Sprague-Dawley rats( 3-4 mo old) from Tyler Laboratories, Bellevue, WA, were used in all the experiments. All surgical procedures were carried out under general anesthesia by intraperitoneal injection of xylazine (2.2 mg/kg, AnaSed; Lloyd Laboratories, Shenandoah, IA) and ketamine (50 mg/kg body wt, Ketaset; Aveco Co., Inc., Fort Dodge, IA).
Labeling ofbFGF. Human recombinant bFGF was a generous gift from Synergen Inc., Boulder, CO. It was labeled with 125I (IMS30, 100 mCi/ ml; Amersham Corp., Arlington Heights, IL) using Iodo-Beads (Pierce Chemical Co., Rockford, IL) following the manufacturer's instructions. The rest of the labeling procedure was carried out as described ( 16) . The specific activity of the labeled bFGF used was -27 and -65 cpm/fmol, respectively.
'25I-bFGF in the vessel wall. The left common carotid artery and segments of the thoracic aorta in rats were denuded of endothelium with a 2F Fogarty balloon catheter as described ( 17) . Five weightmatched pairs of rats were then injected with equal amounts of 1251I bFGF (60 ,g per rat) diluted in 0.2 ml ofsaline. At the indicated times after 1231-bFGF injection, blood samples were drawn by tail vein cannulation and the radioactivity of a 50-MLI plasma sample was measured in a gamma counter (Gamma 5500; Beckman Instruments, Fullerton, CA). 45 min after injection of the radiolabel one rat of each pair received 250 US Pharmacopeia units of standard heparin (. 140 USP units/mg; LyphoMed, Rosemont, IL) intravenously while the corresponding control animal was injected with an equal volume of saline. Blood samples were obtained for measuring '25I-bFGF levels, and 60 min after the heparin/saline administration, the animals were injected with a solution of 5% Evans blue (0.3 ml in saline) to mark the denuded areas. 10 min later the animals were killed, perfused with lactated Ringer's solution, and then perfusion-fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.3). The left carotid artery and thoracic aorta were excised, adhering loose connective tissue was removed, and the denuded segments (blue) and the endothelialized segments of the thoracic aorta were separated. The tissue pieces were airdried and the amount of radiolabel was then quantitated separately in at least three pieces of each denuded carotid, denuded aorta, and endothelialized aorta. The data (cpm/mg dry wt oftissue) obtained from the animals injected with heparin were expressed as a percentage ofthe activity measured in the corresponding control animals which had received saline. Paired Student's t test was used to compare the results. Endogenous bFGF in the vessel wall. Groups ofthree rats received either a bolus injection of heparin (888 USP units/kg body wt) or an equivalent volume ofsaline intravenously immediately before surgery.
Endothelial denudation of the left carotid artery was achieved using three passes of an inflated 2F Fogarty catheter, which damages the medial SMC substantially ( 18, 19) . In sham-operated rats all surgery was performed, with the exception ofendothelial denudation. 9 h after surgery, all rats were killed and their left carotid arteries were processed for immunoblotting or quantitation of bFGF using an immunodetection assay as described below. The data presented here reflect representative results from three independent experiments.
Immunoblotting. Processing of the tissue and immunoblotting were performed as recently described (20) . Briefly, carotid arteries were excised, adhering connective tissue was removed, and the vessels were snap frozen in liquid nitrogen. Three carotid arteries that had been treated in an identical manner were pooled for each sample. The vessels were pulverized under liquid nitrogen with a mortar and pestle and the samples were vortexed in ice-cold cell lysis buffer containing 0.5% SDS, 50 mM Tris, 1 M PMSF, and 10 ,g/ml leupeptin. (21) at a concentration of 4 gg/ml in PBS. All subsequent incubations were carried out at room temperature for 1 h and 3 rinses, with 0.5% BSA in PBS following each incubation. All antibodies were diluted in 1% BSA in PBS. Nonspecific binding was blocked with 1% BSA in PBS containing 2% normal goat serum. Standard dilutions of human recombinant bFGF and test samples (both in triplicate) were then allowed to incubate in the wells, followed by incubation with an affinity-purified polyclonal rabbit antibody against bFGF ( 1 ug/ml). This antibody is described elsewhere (5, 6) . Incubation with a biotinylated goat anti-rabbit IgG antibody (Vector Laboratories, 1:400) was followed by labeling the antibody with peroxidase using an avidin-biotin complex (ABC Elite; Vector Laboratories). The complex was visualized using o-phenylenediamine (1 mg/ml in 0.1 M sodium citrate, pH 4.5). The color reaction was stopped after 30 min with 4.5 M sulfuric acid. Absorbance was then measured at 490 nm using an ELISA reader (Bio-Tek Instruments, Winooski, VT). The concentrations of bFGF in the samples were then calculated using the mean of the triplicate measurements and the standard curve obtained with the recombinant bFGF. The were given subcutaneously 28, 36 , and 44 h after injury. 2 h after the last BrdU injection the animals were killed with an overdose ofsodium pentobarbital (160 mg/kg body wt; Anthony Products Co., Arcadia, CA). Fixation for 5 min by perfusion with 4% paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.3) was followed by excision of the carotid arteries and immersion fixation for 2 h. From the central portion of the carotid arteries, three segments, 4 mm apart, were embedded in paraffin and cross-sections were cut. Proliferating SMC were identified by using a monoclonal antibody against BrdU (Boehringer Mannheim Corp., Indianapolis, IN) and a protocol was followed as described (22) . The number of stained nuclei was counted and the BrdU labeling index ([stained nuclei/total nuclei] X 100) was calculated. (b) The experiment was repeated in sets ofanimals following the identical protocol as described above, with the exception that the administration of heparin/vehicle was delayed until 6 h after surgery. Labeling with BrdU and processing of the tissue was carried out as described in a. (c) Two groups of rats had their left carotid artery denuded with a filament loop as described (18 All proliferation data were analyzed using Student's t test. Data were considered significant if P < 0.05.
Results
Distribution of exogenous '25I-bFGF. The left carotid artery and segments of the thoracic aorta in groups of rats were denuded of endothelium by balloon catheterization. The clearance of '25I-labeled bFGF (Fig. 1 A) from the circulation of those rats was then measured after intravenous injection of 60 sg 125I-bFGF into the tail vein ofeach rat. After an initially very rapid clearance (15, 23) a low-level plateau of '25I-bFGF was reached 15 min after the injection. Immediately after the injection of heparin there was a dramatic increase in '25I-bFGF plasma levels with a concomitantly prolonged half-life of the radiolabel (t1/2 50 min). The highest levels were observed within 5 min after the heparin injection and vehicle had no effect on 251I-bFGF plasma levels.
75 min after the injection of heparin or saline in the above experiment, the animals were injected with Evans blue and then killed. Denuded areas of the thoracic aorta and carotid artery could therefore readily be identified. This allowed us to determine the amount ofradioactively labeled bFGF present in the vessel wall both in normal (endothelialized) and denuded arterial tissue. In saline-treated animals, the amount ofradiolabel detected in deendothelialized aortic tissue was -45-fold higher when compared to endothelialized aortae (Fig. 1 B) . Fig. 1 C shows control value, Fig. 1 C) which is possibly related to heparin's ability to bind to endothelial cells (24).
Heparin and endogenous bFGF in the rat carotid artery. In the experiments described above, heparin was found to displace exogenously added bFGF from a denuded artery. However, this result does not allow us to draw conclusions regarding the fate ofendogenous bFGF. We therefore attempted to determine whether heparin injection after balloon catheter denudation causes a reduction in the amount of detectable endogenous bFGF in the carotid artery. Basic FGF purified from tissue is prone to degradation with subsequent loss of biological activity. We minimized degradation by avoiding any unnecessary purification steps. Immunoblot assays were used to semiquantitatively measure the bFGF content in the vessel wall and to discriminate between the different molecular weight forms of bFGF. In all the experiments the predominant species of bFGF had an apparent molecular mass of 23 kD, which is in agreement with previous data (20) . When a single injection of heparin was given before balloon catheter injury of the carotid artery, a marked reduction in the amount of detectable bFGF was apparent 9 h after injection (Fig. 2 A, lane 4 vs. 5) . In unmanipulated arteries, injection of heparin caused no obvious loss ofendogenous bFGF from those vessels (Fig. 2 A, lane   2 vs. 3) . Using an immunodetection assay we were able to measure directly the concentrations of bFGF in the vessel wall (Fig. 2 B) . After balloon catheter denudation, bFGF levels were reduced to -20% of the controls, and after an injection of heparin, the concentrations of bFGF in balloon injured vessels were below the detection limit. Heparin caused no significant loss of bFGF in unmanipulated vessels (Fig. 2 B) . These findings demonstrate that heparin removes bFGF from traumatized arteries.
Heparin and SMC proliferation. Since a bolus injection of heparin is able to displace bFGF in injured arteries, heparin might be expected to inhibit the proliferative response of SMCs. A bolus injection of heparin (888 USP units/kg) was administered to rats before balloon catheterization of the carotid artery and medial SMC proliferation was determined 2 d later using immunocytochemistry and the thymidine analogue BrdU. Fig. 3 A shows ministration was delayed for 6 h after balloon injury, no reduction in SMC proliferation was observed 2 d later (Fig. 3 B) .
Subsequently we attempted to demonstrate that inhibition of SMC proliferation by heparin is mediated by antagonizing the cellular response to bFGF. Groups of rats had their carotid arteries denuded with the filament loop and immediately after surgery, 60 ug i.v. of bFGF was injected. 15 min later, when most of the bFGF was cleared from circulation ( Fig. 1 A) , one group of rats received a bolus injection of heparin while the control group received vehicle. The proliferation in response to exogenous bFGF was almost completely abolished by the bolus injection of heparin (SMC proliferation 3.5% vs. 21 .9% in the control group) (Fig. 4 A) .
One possibility is that heparin inhibits SMC proliferation by acting directly on the ability of SMC to enter the cell cycle (25, 26). We addressed this issue with the following experiment. Immediately before denudation of their carotid artery with the filament loop, groups ofrats were injected with a bolus of heparin or vehicle. 6 h later, when the heparin was cleared, both groups received an intravenous injection of 60 ug of bFGF. SMC proliferation was measured in an identical time period as for the experiments above. As shown in Fig. 4 B, SMC proliferation was nearly identical in the two groups. These data demonstrate that pretreatment with heparin does not impair the ability of a denuded vessel to respond to bFGF.
Discussion
Heparin inhibits the SMC proliferation and intimal thickening that develops after balloon catheter injury of an artery (7-1 1 ), but the mechanism ofthis inhibition has remained unclear. We have suggested that bFGF released from damaged SMC is responsible for initiation of subsequent SMC proliferation (6) and it is known that bFGF bound to extracellular matrix can be displaced by heparin ( 13, 14) . These observations prompted us to investigate the interaction of heparin with bFGF in the vessel wall. In the present paper we provide evidence that heparin removes bFGF from injured arteries and this mechanism may be responsible for the inhibition of medial SMC proliferation.
'25I-bFGF injected into rabbits is cleared rapidly from the circulation and Thompson et al. (27) noted that heparin caused the reappearance of 251I-bFGF in the plasma. Additional heparin injections did not increase the bFGF plasma concentration. Similar results were obtained in our rat model.
We noted that the increase in 1251I-bFGF plasma concentration was maximal within 5 min after heparin injection and the plasma half-life was approximately 50 min. Presumably the 1251I-bFGF was cleared by metabolic pathways in liver and kidney and the accumulation of radiolabel in the urine supports this (data not shown).
Injection of 1251-bFGF allowed us to measure the amount of radiolabel in untraumatized as well as denuded vessels. Compared to normal arteries, approximately 45-fold more radioactivity was measured in denuded vessels, which suggests that an intact endothelium does indeed function as a barrier reducing the deposition of bFGF into the matrix of the vessel wall. This observation provides a possible explanation for the lack of SMC proliferation in response to infused bFGF in endothelialized arteries (5) . An important finding in our attempt to understand heparin/bFGFinteraction is that an injection ofheparin removes '251-bFGF from denuded arteries. This finding is in accordance with in vitro data ( 13, 14) , which demonstrated that heparin can compete with low affinity binding sites We also show that heparin causes substantial loss ofendogenous bFGF from carotid arteries injured by balloon catheterization and significantly reduces SMC proliferation. In contrast, heparin did not reduce the amount of bFGF in the wall of normal arteries. The fact that heparin was only able to remove bFGF from arteries which were traumatized argues indirectly that bFGF is not present in the extracellular matrix of uninjured arteries. This finding is in agreement with our immunocytochemical staining which reveals predominantly nuclear and cellular localization of bFGF in uninjured rat carotid arteries (6) and a loss of specific cellular staining after balloon injury ( 18) , which supports our suggestion that injury releases bFGF into extracellular sites. The proliferative response of SMCs after filament loop denudation of the rat carotid artery is very low but subsequent administration of bFGF increases SMC proliferation (Fig. 4, A) (5). In this study we anticipated that heparin would interact directly with exogenous bFGF and thereby would reduce bFGF-mediated SMC proliferation. A bolus of heparin almost completely inhibited the bFGF-induced response, suggesting that heparin inhibits SMC replication by displacing bFGF (Fig.   4A ).
Of interest is the apparent discrepancy between the substantial reduction in endogenous bFGF after heparin injection and the estimated 25% loss ofDNA caused by balloon catheterization ( 19) . These data suggest that more bFGF seems be released than can be accounted for by cell death. One conclusion is that bFGF can be released from sublethally damaged SMC. Muthukrishnan et al. (32) have recently demonstrated that bFGF is indeed released very efficiently after a nonlethal injury to cells. The release ofbFGF after injury is not unique to arteries since a recent report shows that a similar situation exists in the cornea where corneal epithelial cells stain positive for bFGF, and the protein is detected in the underlying basement membrane only after lytic cell injury (33) .
One possibility is that heparin acts directly on the cells and its inhibitory action on SMC replication would be unrelated to clearance of bFGF. We therefore tested the ability of SMC to respond to bFGF after pretreatment with heparin. Heparin was administered and bFGF was injected after the whole blood clotting time had returned to normal. Determination of SMC proliferation at an identical time point as in the other experiments above revealed that the ability of SMC to respond to exogenous bFGF was not at all reduced after pretreatment with heparin. The data presented here do not rule out the possibility that heparin inhibits SMC proliferation by mechanisms unrelated to bFGF. Majesky et al. (25) reported that heparin administered by continuous infusion inhibited SMC proliferation even when started as late as 18 h after balloon injury. Since heparin inhibits the expression of a variety of genes (29) it is likely that it has one or more other effects which account for inhibition of SMC migration and intimal thickening. All the experiments in this study, however, are consistent with the hypothesis that inhibition by heparin ofinitial SMC proliferation in injured arteries is due to removal of released bFGF.
